Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay
- 1 November 2013
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 47 (12) , 1635-1640
Abstract
Background: Clinicians managing patients receiving the direct thrombin inhibitor dabigatran may benefit in being able to determine the amount of drug present in selected situations. This may include assessment of accumulation, concurrent drug interactions, or adequate removal from circulation. The ability to estimate the amount of dabigatran present using the chromogenic ecarin assay (ECA) requires further clarification. Objective: To describe the reliability of dabigatran measurements using a chromogenic ECA. Methods: This was an evaluation of the ECA method that incorporated assessment of imprecision, linearity, accuracy, carryover, and lower limits of detection or blank. Pooled normal plasma enriched with dabigatran at concentrations of 0, 25, 50, 75, 100, 125, 150, 200, 300, 400, and 500 ng/mL were sent blinded to 3 laboratories in the United States to compare our ECA results with those of laboratories reporting dilute thrombin time methods (HEMOCLOT thrombin inhibitor assay) for measuring dabigatran. Trough and peak levels from 35 patients were also compared with mass spectrophotometry for assessing ECA accuracy. Results: The within-run or day-to-day imprecision was less than 10%, with high linearity ( R 2 = 0.989) and high degree of accuracy ( R 2 = 0.985; slope = 0.908) for levels ranging between 18 and 470 ng/mL and no carryover at 0 ng/mL noted. The ECA approach appeared to be more reliable at lower dabigatran concentrations. Conclusions: The chromogenic ECA appears to be an effective approach to determine the amount of dabigatran present. Further insights are necessary to determine how it can be used to reduce thromboembolic or bleeding complications in patients receiving dabigatranKeywords
This publication has 14 references indexed in Scilit:
- Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levelsJournal of Thrombosis and Haemostasis, 2013
- Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisJournal of Thrombosis and Haemostasis, 2013
- Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational studyJournal of Thrombosis and Thrombolysis, 2013
- Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro StudyAnnals of Pharmacotherapy, 2012
- Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etexilate TherapyAmerican Journal of Clinical Pathology, 2012
- Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and EffectivenessPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
- Dabigatran EtexilateCirculation, 2011
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activityThrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Ecarin Chromogenic Assay – A New Method for Quantitative Determination of Direct Thrombin Inhibitors Like HirudinPathophysiology of Haemostasis and Thrombosis, 2003